Citigroup In North America offices — Trial modifications decreased by 80.0% to $8.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 42.9%, from $14.00M to $8.00M. This is a positive signal — lower values indicate better performance for this metric.
Higher values indicate a larger portion of the portfolio is under stress and requiring intervention.
The total monetary value of financing receivables that are currently in a trial modification program. This reflects the...
Standard metric for large consumer lenders; peers often disclose this under 'troubled debt restructuring' or 'loan modification' disclosures.
c_segment_in_north_america_offices_trial_modifications| Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.00M | $15.00M | $12.00M | $11.00M | $11.00M | $8.00M | $11.00M | $14.00M | $20.00M | $40.00M | $8.00M |
| QoQ Change | — | -40.0% | -20.0% | -8.3% | +0.0% | -27.3% | +37.5% | +27.3% | +42.9% | +100.0% | -80.0% |
| YoY Change | — | — | — | -56.0% | -26.7% | -33.3% | — | +27.3% | +81.8% | +400.0% | -42.9% |